請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/90240
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 李妮鍾 | zh_TW |
dc.contributor.advisor | Ni-Chung Lee | en |
dc.contributor.author | 莊雅淳 | zh_TW |
dc.contributor.author | Ya-chun Chuang | en |
dc.date.accessioned | 2023-09-24T16:09:46Z | - |
dc.date.available | 2023-11-09 | - |
dc.date.copyright | 2023-09-23 | - |
dc.date.issued | 2023 | - |
dc.date.submitted | 2023-08-03 | - |
dc.identifier.citation | 1. Beutler, E., M. Yeh, and V.F. Fairbanks, The normal human female as a mosaic of X-chromosome activity: studies using the gene for G-6-PD-deficiency as a marker. Proceedings of the National Academy of Sciences, 1962. 48(1): p. 9-16.
2. Gómez-Manzo, S., et al., Glucose-6-phosphate dehydrogenase: update and analysis of new mutations around the world. International journal of molecular sciences, 2016. 17(12): p. 2069. 3. Cappellini, M.D. and G. Fiorelli, Glucose-6-phosphate dehydrogenase deficiency. The lancet, 2008. 371(9606): p. 64-74. 4. Bonsignore, A., et al., Metabolism of human erythrocyte glucose-6-phosphate dehydrogenase: VI. Interconversion of multiple molecular forms. Archives of Biochemistry and Biophysics, 1971. 147(2): p. 493-501. 5. Minucci, A., et al., Glucose-6-phosphate dehydrogenase (G6PD) mutations database: review of the “old” and update of the new mutations. Blood Cells, Molecules, and Diseases, 2012. 48(3): p. 154-165. 6. Pfeffer, D.A., et al., Genetic Variants of Glucose-6-Phosphate Dehydrogenase and Their Associated Enzyme Activity: A Systematic Review and Meta-Analysis. Pathogens, 2022. 11(9): p. 1045. 7. Cunningham, A.D. and D. Mochly-Rosen, Structural analysis of clinically relevant pathogenic G6PD variants reveals the importance of tetramerization for G6PD activity. Matters, 2017. 2017. 8. Group, W.W., Glucose-6-phosphate dehydrogenase deficiency. Bull WHO, 1989. 67: p. 601-611. 9. Beutler, E., G6PD deficiency. 1994. 10. Beutler, E., G6PD: population genetics and clinical manifestations. Blood reviews, 1996. 10(1): p. 45-52. 11. Beutler, E. and S. Duparc, Glucose-6-phosphate dehydrogenase deficiency and antimalarial drug development. The American journal of tropical medicine and hygiene, 2007. 77(4): p. 779-789. 12. Relling, M.V., et al., Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for rasburicase therapy in the context of G6PD deficiency genotype. Clinical Pharmacology & Therapeutics, 2014. 96(2): p. 169-174. 13. Li, Q., et al., Prevalence and molecular characterization of glucose-6-phosphate dehydrogenase deficiency at the China-Myanmar border. PloS one, 2015. 10(7): p. e0134593. 14. Iwai, K., et al., Distribution of glucose-6-phosphate dehydrogenase mutations in Southeast Asia. Human genetics, 2001. 108: p. 445-449. 15. Nkhoma, E.T., et al., The global prevalence of glucose-6-phosphate dehydrogenase deficiency: a systematic review and meta-analysis. Blood Cells, Molecules, and Diseases, 2009. 42(3): p. 267-278. 16. Chien, Y.-H., et al., Changes in incidence and sex ratio of glucose-6-phosphate dehydrogenase deficiency by population drift in Taiwan. Southeast Asian journal of tropical medicine and public health, 2008. 39(1): p. 154. 17. Chiang, S., et al., Neonatal screening for glucose-6-phosphate dehydrogenase deficiency in Taiwan. The Southeast Asian Journal of Tropical Medicine and Public Health, 1999. 30: p. 72-74. 18. Yang, W.-C., et al., Reference levels for glucose-6-phosphate dehydrogenase enzyme activity in infants 7–90 days old in Taiwan. Journal of the Formosan Medical Association, 2020. 119(1): p. 69-74. 19. Luzzatto, L., C. Nannelli, and R. Notaro, Glucose-6-phosphate dehydrogenase deficiency. Hematology/Oncology Clinics, 2016. 30(2): p. 373-393. 20. Chen, C.-H., et al., Targeting aldehyde dehydrogenase 2: new therapeutic opportunities. Physiological reviews, 2014. 94(1): p. 1-34. 21. Li, R., et al., ALDH2 gene polymorphism in different types of cancers and its clinical significance. Life sciences, 2016. 147: p. 59-66. 22. Cai, Q., et al., Association between Glu504Lys polymorphism of ALDH2 gene and cancer risk: a meta-analysis. PLoS One, 2015. 10(2): p. e0117173. 23. Gross, E.R., et al., A personalized medicine approach for Asian Americans with the aldehyde dehydrogenase 2* 2 variant. Annual review of pharmacology and toxicology, 2015. 55: p. 107-127. 24. Shortall, K., et al., Insights into aldehyde dehydrogenase enzymes: a structural perspective. Frontiers in Molecular Biosciences, 2021. 8: p. 659550. 25. Chen, C.-H., A.U. Joshi, and D. Mochly-Rosen, The role of mitochondrial aldehyde dehydrogenase 2 (ALDH2) in neuropathology and neurodegeneration. Acta Neurol Taiwan, 2016. 25(4): p. 111-123. 26. Chen, C.-H., et al., Activation of aldehyde dehydrogenase-2 reduces ischemic damage to the heart. Science, 2008. 321(5895): p. 1493-1495. 27. Xu, D., et al., Mitochondrial aldehyde dehydrogenase attenuates hyperoxia-induced cell death through activation of ERK/MAPK and PI3K-Akt pathways in lung epithelial cells. American Journal of Physiology-Lung Cellular and Molecular Physiology, 2006. 291(5): p. L966-L975. 28. Hsu, L.-A., et al., Aldehyde dehydrogenase 2 ameliorates chronic alcohol consumption-induced atrial fibrillation through detoxification of 4-HNE. International journal of molecular sciences, 2020. 21(18): p. 6678. 29. Chen, C.-H., B.R. Kraemer, and D. Mochly-Rosen, ALDH2 variance in disease and populations. Disease Models & Mechanisms, 2022. 15(6): p. dmm049601. 30. Brooks, P.J., et al., The alcohol flushing response: an unrecognized risk factor for esophageal cancer from alcohol consumption. PLoS medicine, 2009. 6(3): p. e1000050. 31. Pang, J., et al., Targeting acetaldehyde dehydrogenase 2 (ALDH2) in heart failure—recent insights and perspectives. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease, 2017. 1863(8): p. 1933-1941. 32. Hoshi, H., et al., Aldehyde‐stress resulting from Aldh2 mutation promotes osteoporosis due to impaired osteoblastogenesis. Journal of Bone and Mineral Research, 2012. 27(9): p. 2015-2023. 33. Joshi, A.U., et al., Aldehyde dehydrogenase 2 activity and aldehydic load contribute to neuroinflammation and Alzheimer’s disease related pathology. Acta neuropathologica communications, 2019. 7(1): p. 1-18. 34. Marchitti, S.A., et al., Non-P450 aldehyde oxidizing enzymes: the aldehyde dehydrogenase superfamily. Expert opinion on drug metabolism & toxicology, 2008. 4(6): p. 697-720. 35. Luo, H.-R., et al., Origin and dispersal of atypical aldehyde dehydrogenase ALDH2⁎ 487Lys. Gene, 2009. 435(1-2): p. 96-103. 36. Yokoyama, A., T. Omori, and T. Yokoyama, Alcohol and aldehyde dehydrogenase polymorphisms and a new strategy for prevention and screening for cancer in the upper aerodigestive tract in East Asians. The Keio journal of medicine, 2010. 59(4): p. 115-130. 37. Wang, Q., et al., Role of ALDH2 in hepatic disorders: gene polymorphism and disease pathogenesis. Journal of Clinical and Translational Hepatology, 2021. 9(1): p. 90. 38. Farrés, J., et al., Effects of changing glutamate 487 to lysine in rat and human liver mitochondrial aldehyde dehydrogenase. A model to study human (Oriental type) class 2 aldehyde dehydrogenase. Journal of Biological Chemistry, 1994. 269(19): p. 13854-13860. 39. Lai, C.L., et al., Dominance of the inactive Asian variant over activity and protein contents of mitochondrial aldehyde dehydrogenase 2 in human liver. Alcoholism: Clinical and Experimental Research, 2014. 38(1): p. 44-50. 40. Chen, Y.-C., et al., Pharmacokinetic and pharmacodynamic basis for overcoming acetaldehyde-induced adverse reaction in Asian alcoholics, heterozygous for the variant ALDH2* 2 gene allele. Pharmacogenetics and genomics, 2009. 19(8): p. 588-599. 41. Jin, S., et al., ALDH2 (E487K) mutation increases protein turnover and promotes murine hepatocarcinogenesis. Proceedings of the National Academy of Sciences, 2015. 112(29): p. 9088-9093. 42. Chen, C.-H., et al., Novel and prevalent non-East Asian ALDH2 variants; Implications for global susceptibility to aldehydes’ toxicity. EBioMedicine, 2020. 55. 43. Hwang, S., et al., Correcting glucose-6-phosphate dehydrogenase deficiency with a small-molecule activator. Nature communications, 2018. 9(1): p. 4045. 44. Benfeitas, R., et al., Characterization of heterogeneous redox responses in hepatocellular carcinoma patients using network analysis. EBioMedicine, 2019. 40: p. 471-487. 45. Benfeitas, R., et al., New challenges to study heterogeneity in cancer redox metabolism. Frontiers in cell and developmental biology, 2017. 5: p. 65. 46. Brown, G.C. and V. Borutaite, There is no evidence that mitochondria are the main source of reactive oxygen species in mammalian cells. Mitochondrion, 2012. 12(1): p. 1-4. 47. Nathan, C. and A. Cunningham-Bussel, Beyond oxidative stress: an immunologist's guide to reactive oxygen species. Nature Reviews Immunology, 2013. 13(5): p. 349-361. 48. Hornsveld, M. and T.B. Dansen, The hallmarks of cancer from a redox perspective. Antioxidants & redox signaling, 2016. 25(6): p. 300-325. 49. Fulda, S., L. Galluzzi, and G. Kroemer, Targeting mitochondria for cancer therapy. Nature reviews Drug discovery, 2010. 9(6): p. 447-464. 50. Zhang, C., et al., Glucose-6-phosphate dehydrogenase: a biomarker and potential therapeutic target for cancer. Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry-Anti-Cancer Agents), 2014. 14(2): p. 280-289. 51. Debeb, B.G., et al., Histone deacetylase inhibitor-induced cancer stem cells exhibit high pentose phosphate pathway metabolism. Oncotarget, 2016. 7(19): p. 28329. 52. Hou, G., et al., Aldehyde dehydrogenase‐2 (ALDH2) opposes hepatocellular carcinoma progression by regulating AMP‐activated protein kinase signaling in mice. Hepatology, 2017. 65(5): p. 1628-1644. 53. Zhang, X., et al., Identification of a subtype of hepatocellular carcinoma with poor prognosis based on expression of genes within the glucose metabolic pathway. Cancers, 2019. 11(12): p. 2023. 54. Millwood, I.Y., et al., Conventional and genetic evidence on alcohol and vascular disease aetiology: a prospective study of 500 000 men and women in China. The Lancet, 2019. 393(10183): p. 1831-1842. 55. Santana, M.S., et al., High frequency of diabetes and impaired fasting glucose in patients with glucose-6-phosphate dehydrogenase deficiency in the Western brazilian Amazon. The American journal of tropical medicine and hygiene, 2014. 91(1): p. 74. 56. Stanton, R.C., Glucose‐6‐phosphate dehydrogenase, NADPH, and cell survival. IUBMB life, 2012. 64(5): p. 362-369. 57. Mejía, S.Á., et al., Nicotinamide prevents sweet beverage-induced hepatic steatosis in rats by regulating the G6PD, NADPH/NADP+ and GSH/GSSG ratios and reducing oxidative and inflammatory stress. European journal of pharmacology, 2018. 818: p. 499-507. 58. Pes, G.M., G. Parodi, and M.P. Dore, Glucose-6-phosphate dehydrogenase deficiency and risk of cardiovascular disease: A propensity score-matched study. Atherosclerosis, 2019. 282: p. 148-153. 59. Hecker, P.A., et al., Impact of glucose-6-phosphate dehydrogenase deficiency on the pathophysiology of cardiovascular disease. American Journal of Physiology-Heart and Circulatory Physiology, 2013. 304(4): p. H491-H500. 60. Heymann, A.D., Y. Cohen, and G. Chodick, Glucose-6-phosphate dehydrogenase deficiency and type 2 diabetes. Diabetes care, 2012. 35(8): p. e58-e58. 61. Mali, V.R., et al., Impairment of aldehyde dehydrogenase-2 by 4-hydroxy-2-nonenal adduct formation and cardiomyocyte hypertrophy in mice fed a high-fat diet and injected with low-dose streptozotocin. Experimental Biology and Medicine, 2014. 239(5): p. 610-618. 62. Okura, T., et al., Aldehyde dehydrogenase 2 polymorphism is an important gene for insulin resistance in Japanese patients with type 2 diabetes. Metabolism Open, 2023. 18: p. 100242. 63. Hu, N., J. Ren, and Y. Zhang, Mitochondrial aldehyde dehydrogenase obliterates insulin resistance-induced cardiac dysfunction through deacetylation of PGC-1α. Oncotarget, 2016. 7(47): p. 76398. 64. Wohlfart, D.P., et al., Accumulation of acetaldehyde in aldh2. 1−/− zebrafish causes increased retinal angiogenesis and impaired glucose metabolism. Redox Biology, 2022. 50: p. 102249. 65. Gao, J., et al., Aldehyde dehydrogenase 2 as a therapeutic target in oxidative stress-related diseases: post-translational modifications deserve more attention. International journal of molecular sciences, 2022. 23(5): p. 2682. 66. Mbanefo, E.C., et al., Association of glucose-6-phosphate dehydrogenase deficiency and malaria: a systematic review and meta-analysis. Scientific reports, 2017. 7(1): p. 45963. 67. Chen, C.-C., et al., Interaction between the functional polymorphisms of the alcohol-metabolism genes in protection against alcoholism. The American Journal of Human Genetics, 1999. 65(3): p. 795-807. 68. Stevens, D., et al., G6PD Canton a common deficient variant in South East Asia caused by a 459 Arg----Leu mutation. Nucleic acids research, 1990. 18(23): p. 7190. 69. Wagner, G., K. Bhatia, and P. Board, Glucose-6-phosphate dehydrogenase deficiency mutations in Papua New Guinea. Human biology, 1996: p. 383-394. 70. Ng, C.S., et al., ALDH2 polymorphism, alcohol intake and the attributable burden of cancer in East Asia: systematic review, meta-analysis, and modelling study. Annals of Epidemiology, 2023. 71. YU, M.-W., et al., Association between glucose-6-phosphate dehydrogenase deficiency and neonatal jaundice: interaction with multiple risk factors. International journal of epidemiology, 1992. 21(5): p. 947-952. 72. Huang, C.S., et al., Neonatal jaundice and molecular mutations in glucose‐6‐phosphate dehydrogenase deficient newborn infants. American Journal of Hematology, 1996. 51(1): p. 19-25. 73. Chang, J.-G., et al., Molecular characterization of glucose-6-phosphate dehydrogenase (G6PD) deficiency by natural and amplification created restriction sites: five mutations account for most G6PD deficiency cases in Taiwan. 1992. 74. Rinaldi, A., G. Filippi, and M. Siniscalco, Variability of red cell phenotypes between and within individuals in an unbiased sample of 77 heterozygotes for G6PD deficiency in Sardinia. American journal of human genetics, 1976. 28(5): p. 496. 75. Li, Z., et al., Genotypic and phenotypic characterization of glucose-6-phosphate dehydrogenase (G6PD) deficiency in Guangzhou, China. Human Genomics, 2023. 17(1): p. 26. 76. Lin, Y.-P. and T.-J. Cheng, Why can't Chinese Han drink alcohol? Hepatitis B virus infection and the evolution of acetaldehyde dehydrogenase deficiency. Medical hypotheses, 2002. 59(2): p. 204-207. 77. Goldman, D. and M.-A. Enoch, Genetic epidemiology of ethanol metabolic enzymes: a role for selection. World review of nutrition and dietetics, 1990. 63: p. 143-160. 78. Jiang, Y., et al., Alcohol metabolizing enzymes, microsomal ethanol oxidizing system, cytochrome P450 2E1, catalase, and aldehyde dehydrogenase in alcohol-associated liver disease. Biomedicines, 2020. 8(3): p. 50. | - |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/90240 | - |
dc.description.abstract | 背景
6-磷酸葡萄糖脫氫酶(G6PD)缺乏與乙醛去氫酶(ALDH2)缺乏是兩種常見的代謝酵素缺乏疾病。目前已有許多臨床研究證實這兩個基因的表現會影響癌症的預後。此二者基因的缺陷也會造成包括肥胖、葡萄糖代謝異常、脂肪肝、腎功能受損和心血管病病。若同時帶有此二酵素的缺陷,有可能會加重葡萄糖代謝異常及其他器官的損傷。 6-磷酸葡萄糖脫氫酶(G6PD)缺乏與乙醛去氫酶(ALDH2)缺乏的分佈均具有地域性,目前推測此為拓荒者效應的結果。6-磷酸葡萄糖脫氫酶(G6PD)缺乏已被證實針對瘧疾有保護的作用,乙醛去氫酶(ALDH2)缺乏則被認為可能會減少帶因者酒精的攝取,進而減少肝癌的發生。在台灣6-磷酸葡萄糖脫氫酶(G6PD)缺乏與乙醛去氫酶(ALDH2)缺乏的發生率相較於其他地區均明顯較高,但目前還未有研究調查同時發生6-磷酸葡萄糖脫氫酶與乙醛去氫酶缺乏的比率。因此,我們想要調查在台灣6-磷酸葡萄糖脫氫酶與乙醛去氫酶缺乏的基因型,並嘗試釐清在蠶豆症患者中,乙醛去氫酶缺乏症患者的比率是否較高。 研究目的 分析乙醛去氫酶基因缺損與6-磷酸葡萄糖脫氫酶基因缺損與否的關聯性。同時統計各乙醛去氫酶缺損與6-磷酸葡萄糖脫氫酶缺損之基因型在台灣地區的比率。 研究方法 本研究回朔性收錄於2010年1月至2022年5月這段期間,於台大醫院接受全外顯子定序的個案共594位,使用MViewer分析各患者於G6PD與ALDH2基因中帶有的致病性變異的比率,並嘗試分析各基因型患者可能出現的表現型。 研究結果 在594位個案中,共26位個案帶有致病性的G6PD基因變異(帶因率為4.4%),共284位個案帶有致病性的ALDH2基因變異(帶因率為47.8%)。分析G6PD基因變異的個案,可發現NM_000402.4(G6PD):c.1466G>T (p.Arg489Leu)變異的帶因率為所有G6PD基因中最高,約佔所有G6PD基因變異的50%。在ALDH2基因變異的帶因者中,幾乎所有的帶因者均帶有NM_000690.4(ALDH2):c.1510G>A (p.Glu504Lys)變異。比較帶因率可發現在帶有致病性的G6PD基因變異的個案族群中帶有致病性的ALDH2基因變異的比率較高,但未達統計顯著(65.4% v.s. 47.0%, P=0.067, 檢定力= 0.496)。 結論 我們的回顧性分析顯示台灣人群中 ALDH2 和 G6PD 缺乏症的患病率較世界平均為高。我們也觀察到相較於未帶有G6PD 基因缺陷的族群,在帶有G6PD 基因缺陷的族群,帶有ALDH2 基因缺陷的比例有上升的趨勢。 然而,由於目前缺乏基因型和表現型關聯性的研究,同時帶有此二者基因缺陷對各酵素活性的影響與可能造成臨床疾病均需要更進一步的研究來驗證。 | zh_TW |
dc.description.abstract | Background
Both G6PD and ALDH2 genes encode multimeric metabolic enzymes that play critical roles in mitigating oxidative stress within human cells. The expression of two genes were proved to have a great influence in clinical outcome of hepatocellular carcinoma, renal cell carcinoma, and other kinds of cancer. According to other studies, a lack of these enzymes has been linked to obesity, aberrant glucose metabolites, fatty liver, impaired renal function, and cardiovascular disease. The distribution of G6PD and ALDH2 deficiency was strong geographical correlated. This may be the cause of fundal effect. G6PD deficiency was proved to have protected effect of malaria while ALDH2 deficiency would prevent the carrier from alcohol abused. Though the prevalence of G6PD and ALDH2 deficiency were both high in Taiwan, no prior studies have addressed the potential risk of concurrent G6PD and ALDH2 deficiency. Therefore, the study's objective is to elucidate the genotype distribution of G6PD deficiency and ALDH2 deficiency. Additionally, we also want to investigate whether ALDH2 deficiency is more commonly observed in patients with a G6PD pathogenic variant. Aim Using whole exome sequencing to analyze the genotype of G6PD and ALDH2 deficiency in Taiwan and try to figure out weather G6PD deficiency was a predictive factor of ALDH2 deficiency. Material and Method The study was conducted in National Taiwan University Hospital. We retrospectively reviewed the genomic data of the patient who underwent whole exome sequencing form January, 2010 to May, 2022. 594 patients were recruited in our study. Pathogenic variant classified according to ACMG interpretation criteria or ClinVar clinical significance data base were called with MViewer. The incidence of all kinds of pathogenic variants were calculated. Result Among 594 cases, 26 cases carried a pathogenic variant in G6PD gene (carrier rate 4.4%) and 284 cases carried a pathogenic variant in ALDH2 gene (carrier rate 47.8%). NM_000690.4(ALDH2):c.1510G>A (p.Glu504Lys) was the most common pathogenic variant of G6PD gene in our study population. NM_000690.4(ALDH2):c.1510G>A (p.Glu504Lys) were presented in nearly all of the carriers of pathogenic variant in ALDH2 gene. Compared with those without pathogenic G6PD variant, patient with G6PD pathogenic variant were more likely to suffered from ALDH2 deficiency (65.4% v.s. 47.0%, p = 0.0067). However, our results did not reach statistic significance due to relative small example. Conclusion Our retrospective study revealed that the incidence of G6PD and ALDH2 deficiency were relatively high in Taiwan. We also found that there was a trend of an increasing proportion of ALDH2 deficiency among the G6PD deficient group. Though, due to lack of phenotype study, the precise relationship between mutations in these genes and clinical manifestation remain unclear. Further study is required for exploring these relationships and clarify their implications for health and disease. | en |
dc.description.provenance | Submitted by admin ntu (admin@lib.ntu.edu.tw) on 2023-09-24T16:09:46Z No. of bitstreams: 0 | en |
dc.description.provenance | Made available in DSpace on 2023-09-24T16:09:46Z (GMT). No. of bitstreams: 0 | en |
dc.description.tableofcontents | 中文摘要 4
ABSTRACT 6 CONTENT 8 LIST OF FIGURES 10 LIST OF TABLE 11 CHAPTER 1 INTRODUCTION 12 1.1 The importance of G6PD gene in our daily life 12 1.2 The importance of ALDH2 gene in reducing oxidative stress 15 1.3 Interaction between G6PD gene and ALDH2 gene 19 CHAPTER 2 MATERIAL AND METHODS 22 2.1 Data collection 22 2.2 Whole exome sequencing 23 2.3 Variant annotation and filtering 23 2.4 Statistical analysis 24 CHAPTER 3 RESULT 25 3.1 Variants of ALDH2 in the studied population 25 3.2 Variants of G6PD in the studied population 25 3.3 Frequency of concurrence of ALDH2 and G6PD deficiency 26 CHAPTER 4 DISCUSSION 29 4.1 ALDH2 gene polymorphism in Taiwan and the effect of ALDH2 enzyme deficiency 29 4.2 Compared the prevalence of G6PD deficiency between our study and previous data 30 4.3 Patients who carried G6PD pathogenic variant was more likely to carried ALDH2 pathogenic variant in Taiwan 32 4.4 Limitation 33 CHAPTER 5 CONCLUSION 35 REFERENCE 35 | - |
dc.language.iso | en | - |
dc.title | 以全外顯子定序分析ALDH2基因和G6PD 基因缺陷間的關係 | zh_TW |
dc.title | Deficiency “connected” trail of ALDH2 and G6PD deficiency using whole exome sequencing | en |
dc.type | Thesis | - |
dc.date.schoolyear | 111-2 | - |
dc.description.degree | 碩士 | - |
dc.contributor.oralexamcommittee | 胡務亮;簡穎秀;蕭勝文 | zh_TW |
dc.contributor.oralexamcommittee | Wuh-Liang Hwu;Yin-Hsiu Chien;Steven W. Shaw | en |
dc.subject.keyword | 6-磷酸葡萄糖脫氫酶,乙醛去氫酶,活性氧化物質,次世代定序,基因診斷, | zh_TW |
dc.subject.keyword | Glucose-6-phosphate Dehydrogenase (G6PD),Aldehyde Dehydrogenase (ALDH2),Reactive oxygen species (ROS),next generation sequencing,genomic diagnosis, | en |
dc.relation.page | 48 | - |
dc.identifier.doi | 10.6342/NTU202302386 | - |
dc.rights.note | 同意授權(限校園內公開) | - |
dc.date.accepted | 2023-08-04 | - |
dc.contributor.author-college | 醫學院 | - |
dc.contributor.author-dept | 分子醫學研究所 | - |
dc.date.embargo-lift | 2028-07-29 | - |
顯示於系所單位: | 分子醫學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-111-2.pdf 目前未授權公開取用 | 2.92 MB | Adobe PDF | 檢視/開啟 |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。